Neimeth International Pharmaceuticals Plc is seeking shareholder approval for a N1.98 billion capital restructuring that could significantly reshape its balance sheet and future dividend capacity.
The move follows a February 5, 2026, order of the Federal High Court directing the company to conven
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
